Products
Tucotuzumab Biosimilar Antibody-Drug Conjugate (EpCAM) for Research
Cat No.: GMP-Bios-INN-1431
Anti-EPCAM/CD326 therapeutic antibody (Pre-made Tucotuzumab biosimilar,Whole mAb ADC) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Tucotuzumab (development code EMD-273066, also known as tucotuzumab celmoleukin) is a humanized monoclonal antibody fusion protein targeting epithelial cell adhesion molecule (EpCAM/EPCAM), in which the antibody is fused to interleukin-2. It is developed by EMD Lexigen and Merck KGaA for ovarian cancer and small cell lung cancer in Phase II development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1431-1mg | 1mg | 4635 |
| GMP-Bios-INN-1431-10mg | 10mg | |
| GMP-Bios-INN-1431-100mg | 100mg | |
| GMP-Bios-INN-1431-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Tucotuzumab biosimilar, Whole mAb ADC, Anti-EPCAM/CD326 Antibody: Anti-EPCAM/CD326/Epithelial cell adhesion molecule/Ep-CAM therapeutic antibody |
| INN Name | Tucotuzumab |
| Target | EPCAM/CD326 |
| Format | Whole mAb ADC |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Discontinued |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2005 |
| Year Recommended | 2006 |
| Companies | EMD Lexigen;Merck KGaA |
| Conditions Approved | na |
| Conditions Active | na |
| Conditions Discontinued | Ovarian cancer;Small cell lung cancer |
| Production | na |
| Development Tech | na |
